|
Match
|
Document |
Document Title |
|
|
7387271 |
Immunostimulatory combinations
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also...
|
|
|
7368119 |
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
|
|
|
7364741 |
Peptides of human Papilloma virus for use in human T cell response inducing compositions
A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex...
|
|
|
7361360 |
Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation...
|
|
|
7361346 |
Therapeutic compositions that produce an immune response
The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent...
|
|
|
7355012 |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and...
|
|
|
7355011 |
Biological products
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein...
|
|
|
7329410 |
Compositions and method for WT1 specific immunotherapy
A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated...
|
|
|
7326767 |
Immunotherapeutic methods using epitopes of WT-1 and GATA-1
A peptide comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino...
|
|
|
7317086 |
Basal cell carcinoma tumor suppressor protein
This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a...
|
|
|
7306797 |
Use of a compound antagonist of ESM-1 protein for producing a medicine for treating cancer
Use of an antagonist compound of protein ESM-1 for the production of a drug for the treatment of a cancer.
|
|
|
7285282 |
Mucin peptide with immunoenhancing properties
An isolated peptide or polypeptide containing the sequence VSIGLSFPMLP (SEQ ID NO:1), found in the secreted form of human MUC1, that enhances an immune response when administered to a mammal,...
|
|
|
7279156 |
Apoptotic entities for use in treatment of endothelium dysfunction disorders
Treatment and/or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic...
|
|
|
7264820 |
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a...
|
|
|
RE39789 |
Tumor therapy
Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and...
|
|
|
7252829 |
HLA binding peptides and their uses
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles...
|
|
|
7252825 |
MAGE-3 peptides presented by HLA class II molecules
The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides...
|
|
|
7247310 |
Tumor vaccines
A tumor vaccine which comprises a microparticle or a lysate prepared from a solidified tumor material selected from the group consisting of a tumor tissue, a tumor cell, and a component thereof,...
|
|
|
7241441 |
Microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities
The present invention relates to a novel Pediococcus genus microorganism and more particularly, Pediococcus pentosaceus EROM101 (KCCM-10517) originated from human intestines having immune...
|
|
|
7238360 |
Alteration of cell membrane with B7
Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene...
|
|
|
7232682 |
Expression vectors encoding epitopes of target-associated antigens and methods for their design
The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing...
|
|
|
7229628 |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is...
|
|
|
7226606 |
Cancer-associated antigens and methods of their identification and use
The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in...
|
|
|
7202334 |
Compositions and methods for the therapy and diagnosis of ovarian cancer
Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions...
|
|
|
7163703 |
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt,...
|
|
|
7160856 |
α-O-linked glycoconjugates, methods of preparation and uses thereof
The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified...
|
|
|
7160544 |
Method of vaccinating vertebrates
The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a...
|
|
|
7157091 |
MAGE-A1 peptides presented by HLA class II molecules
The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid...
|
|
|
7147855 |
GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical...
|
|
|
7144581 |
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
|
|
|
7135188 |
Methods and compositions for immunotherapy of cancer
Methods and vaccines for suppressing formation of or inhibiting growth of tumors in a host are provided, via administration of a vaccine containing either a fusion protein of the tumor associated...
|
|
|
7132109 |
Using heat shock proteins to increase immune response
The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or...
|
|
|
7118924 |
Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes...
|
|
|
7115272 |
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise a WT1 polypeptide comprising an immunogenic portion of WT1,...
|
|
|
7109026 |
Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen...
|
|
|
7105162 |
Pharmaceutical composition for immunomodulation based on peptides and adjuvants
Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a...
|
|
|
7105161 |
Proteinaceous adjuvants
A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host....
|
|
|
7105155 |
Method and activated lymphocyte preparations for preventing recurrence of carcinoma
Activated lymphocytes are administered to a cancer patient at least five or more times within eight months after performing surgical and chemotherapeutic treatment or radiotherapy for treating...
|
|
|
7098311 |
Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
The invention provides isolated nucleic acids molecules, designated jAZF1, jjAZ1 or jAZF1/jjAZ1 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant...
|
|
|
7098306 |
Method and compositions for treating hepatocellular cancer
A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface. The method comprises creating an...
|
|
|
7097846 |
35 kD tumor associated protein antigen: uses and methods of detection
This invention provides the isolation and characterization of a tumor associated antigen which can be used for immunodiagnosis, immunoprognosis, and therapy of human cancer. The antigen is a...
|
|
|
7063854 |
Composition and methods for WTI specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
|
|
|
7060284 |
Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the...
|
|
|
7060279 |
Compositions and methods for dendritic cell-based immunotherapy
Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins...
|
|
|
7056689 |
Methods of treating and detecting cancer using viruses
The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The...
|
|
|
7052703 |
T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof
This invention provides nucleic acids containing sequences from a TCRγ transcript from prostate epithelial cells and many breast cancer cells and a T-cell receptor gamma Alternate Reading frame...
|
|
|
7041302 |
Therapeutic modulation of the tumor inflammatory response
The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1...
|
|
|
7022819 |
Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which...
|
|
|
7022496 |
Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA
The present invention provides a modified adenovirus comprising genomic adenoviral DNA which has been modified so that (i) the only gene product of the early region (E4) that is expressed is open...
|
|
|
7018637 |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbohydrate fragments each linker to the carrier molecule and...
|